The US FDA has given its blessing to Corbus Pharmaceuticals Holdings Inc. to use pulmonary exacerbations as the sole primary endpoint for a potentially registrational study of lenabasum in cystic fibrosis, a development that could help the product get to market much more quickly than if a forced expiration volume measure were used, according to CEO Yuval Cohen.
Lenabasum (formerly called anabasum) is a synthetic, oral small molecule that preferentially binds to the cannabinoid receptor 2 (CB2) expressed...







